Despite promising clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial resistance from pharmacy benefit managers. Such organizations are typically creating barriers to access, like significant cost criteria and prior authorization that restrict patient access. An